Rheumatoid Arthritis Stem Cell Therapy Market

Rheumatoid Arthritis Stem Cell Therapy Market Outlook

The stem cells with the ability to stimulate regeneration, immune modulating capacity, and excellent anti-inflammatory activity can be screened and selected. In addition, an abundant amount of mesenchymal stem cells can be obtained from umbilical cord tissue. These are some of the key factors favoring the development of the rheumatoid arthritis stem cell therapy market.

Rheumatoid arthritis stem cell therapy has been demonstrated to induce profound healing activity, halt arthritic conditions, and in many cases, reverse and regenerate joint tissue. Today, bone marrow transplants, adipose or fat-derived stem cells, and allogeneic mesenchymal stem cells (human umbilical cord tissue) are used for rheumatoid arthritis stem cell therapy.

Governments are heavily investing in healthcare sectors which in turn is expected to fuel the growth of the rheumatoid arthritis stem cell therapy market. Growing research to find an effective treatment for various autoimmune disorders will possibly create potential growth prospects for the rheumatoid arthritis stem cell therapy market.

The global rheumatoid arthritis stem cell therapy market account for a share of USD 23.42 Billion in 2022. The market is anticipated to surpass the valuation of USD 33.30 Billion by end of the forecast period i.e. 2032. The rheumatoid arthritis stem cell market is expected to grow with a CAGR of 4.5 %.

As rheumatoid arthritis worsens, the body initiates an autoimmune response and attacks the cells. Rheumatoid arthritis stem cell therapy is growing in popularity across hospitals, ambulatory surgical centers, and specialty clinics, as it increases the healing of joints and further treats the entire system that causes joint pain and inflammation. Rheumatoid arthritis stem cell therapy is an alternative option as the therapy works to induce healing while regenerating healthy tissue.

Report Attributes	Details
Rheumatoid Arthritis Stem Cell Therapy Market size (2022A)	USD 23.42 Billion
Base Year for Estimation	2022
Forecast duration for this research	2022-2032
Forecasted Market value (2032F)	USD 33.30 Billion
Global Market Growth rate (2022-2032E)	CAGR of 4.5 %
Key Companies Profiled	Mesoblast Ltd Roslin Cells Regeneus Ltd ReNeuron Group plc International Stem Cell Corporation TiGenix

Impulses of Rheumatoid arthritis stem cell therapy

The growing prevalence and recurrence of rheumatoid arthritis are expected to be the major factor driving the growth of the rheumatoid arthritis stem cell therapy market over the forecast period. Although doctors do not know the exact cause of rheumatoid arthritis, certain risk factors are observed to be associated with it. These risk factors include age (most common between the age of 40 and 60), family history, gender, environment (a toxic chemical in the environment can up the odds), obesity, and smoking.

Changes in lifestyle and eating habits are contributing to the growing prevalence of rheumatoid arthritis. The development and addition of new therapies is the other factor contributing to the growth of the global rheumatoid arthritis stem cell therapy market. For instance, Belgian company TiGenix announced a randomized phase II trial of its adipose-derived stem cell product Cx611. This treatment is intended for patients who have active rheumatoid arthritis despite being treated with methotrexate and steroids.

Impacts of Rheumatoid arthritis stem cell therapy

“Rheumatoid arthritis stem cell therapy has to modulate effect on the immune system”

Rheumatoid arthritis stem cell therapy also has a modulating effect on the immune system, which helps in fighting diseases while turning off some of the pathological responses. Today, new treatments and advances in rheumatoid arthritis research are being studied. Rheumatoid arthritis stem cell therapy is being studied for its efficacy in improving complications in patients through the use of their own stem cells. These stem cell therapies may help patients who do not respond to typical drug treatment and want to reduce their reliance on medications or who are looking to try stem cell therapy before starting drug treatment.

Impact of the Covid-19 Pandemic on the Rheumatoid arthritis stem cell therapy Market

The pandemic has had a negative impact on the financial ability of patients leading to the postponement of surgeries by them. These trends affected revenue generation in the field. This also has opened opportunities for medical practitioners to ensure a healthy environment and risk-free operations of patients.

The global market for rheumatoid arthritis stem cell therapy is expected to witness moderate growth over the forecast period. A majority of Rheumatoid arthritis stem cell therapy is available in various hospitals, orthopedic clinics, ambulatory surgical centers, and specialties. Amongst the end users in the Rheumatoid arthritis stem cell therapy market, the hospitals and ambulatory surgical centers segments are expected to lead in the global Rheumatoid arthritis stem cell therapy market over the forecast period.

Segment wise analysis

Based on the type of treatment the Allogeneic Mesenchymal Stem Cells and Adipose Tissue Stem Cells are dominating segments over that of a bone marrow transplant. The process of collecting stem cells from the bloodstream is easier than from bone marrow. Also, stem cell therapies are popular because they are effective in blood counts and quick recovery. Nearly 50000 steam cell transplants occur annually owing to their impact in making patients recover soon.

On the basis of end users, this market is dominated by hospitals and orthopedics. The hospitals see large rheumatoid arthritis stem cell therapy rates owing to the availability of government funds that give financial relief to patients undergoing surgery. Alongside these hospitals are anticipated to experience a rise in patients due to increasing injuries in the forecast duration.

Regional Insights

Geographically, the global rheumatoid arthritis stem cell therapy market can be segmented into viz. North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan, and the Middle East and Africa (MEA). North America is expected to be the dominant region in the global rheumatoid arthritis stem cell therapy market, owing to the presence of various key players.

The rheumatoid arthritis stem cell therapy market in Asia Pacific excluding Japan is expected to grow at a significant CAGR due to the expansion of product offerings by key players. Europe is expected to have the second large share in the global rheumatoid arthritis stem cell therapy market throughout the forecast period.

Global Rheumatoid Arthritis Stem Cell Therapy Industry Segments:

Tentatively, the global rheumatoid arthritis stem cell therapy market can be segmented on the basis of treatment type, application, end-user, and geography.

• By Treatment Type:

  • Allogeneic Mesenchymal stem cells
  • Bone marrow Transplant
  • Adipose Tissue Stem Cells

• By Application :

  • Rheumatoid Arthritis Stem Cell Therapy

• By Distribution Channel:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

• By Geography :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific
  • Japan
  • China
  • Middle-East & Africa